PROVECTUS BIOPHARMS - PVCT STOCK NEWS

Provectus Biopharmaceuticals, Inc. announces the USPTO's allowance of three patent applications related to the use of rose bengal sodium in oncology, virology, and as a vaccine adjuvant. The patents cover various applications of the drug substance in treating infectious diseases, pediatric solid tumors, and enhancing vaccine effectiveness.

Provectus Biopharmaceuticals, Inc. announces preclinical findings on PV-10 for HPV-positive and HPV-negative HNSCC, showing induction of immunogenic cell death and anti-tumor immunity. The research conducted by Moffitt Cancer Center reveals significant cytotoxicity, increase in reactive oxygen species, and markers of immunogenic cell death both in vitro and in vivo.

Provectus Biopharmaceuticals, Inc. announced preclinical research on the topical administration of rose bengal sodium for wound healing. The data will be presented at the annual meeting of the Society for Investigative Dermatology in May 2024.

Provectus Biopharmaceuticals, Inc. to Host Conference Call for Company Updates on February 22, 2024

Provectus Biopharmaceuticals, Inc. has partnered with IR Labs, Inc. to enhance its investor relations and corporate communications program. The collaboration aims to boost investor communication, engagement, and visibility within the investment community.

Provectus (PVCT) has received patent approval from the USPTO for the use of its rose bengal sodium (RBS) drug substance as an adjuvant in vaccines. The patent covers the potential use in anticancer, antiviral, and other vaccines, with the potential to enhance T-cell response. The research underlying the patent was led by Dr. Aru Narendran and his lab team, with promising preclinical data presented at the SITC 2023 annual meeting. The patent award marks Provectus's first in the field of vaccines from the USPTO, with Innovate Calgary as a co-assignee.

Provectus (OTCQB: PVCT) provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 in combination with standard of care immune checkpoint blockade for advanced cutaneous melanoma. Initial results from CB-naïve patients in the main study cohort showed potential clinical benefit across all stages of metastasis. Longer-term follow-up of an expanded patient population has been assessed, revealing promising outcomes. The primary endpoint of the Phase 1b portion was safety and tolerability, with objective response rate (ORR) and progression-free survival (PFS) as key secondary endpoints. Treatment-emergent adverse events were consistent with established patterns of both study drugs. For all CB-naïve patients, the ORR was 72%, with a median PFS of 12.5 months and a median overall survival (mOS) of 37.6 months. For CB-naïve Stage III patients, the ORR was 83%, with rapid and durable complete responses and estimated mOS and median disease-specific survival (mDSS) of 36.3 months and 42.5 months, respectively.

Provectus (OTCQB: PVCT) provides updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 for the treatment of uveal melanoma metastatic to the liver. The data shows acceptable safety, objective response rates, and median overall survival, with positive outcomes for patients receiving PV-10, either as monotherapy or in combination with immune checkpoint blockade (CB). The company plans to expand the study to confirm the initial results.

Provectus announces preclinical data on the potential use of PV-10 as an adjuvant in vaccines. The research shows PV-10's ability to enhance T-cell responses and improve immune response to vaccination. PV-10 could be used in anti-viral, anti-cancer, and other vaccines.